Navigation Links
Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/14/2008

DALLAS, May 14 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it will make a presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference to be held May 19-20, 2008 at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Jeffrey B. Davis, CEO of Access is scheduled to speak on Monday, May 19, 2008 at 3:10 pm local time, 9:10 am Eastern time and will give a corporate overview and discuss the Company's product opportunities.

The presentation will be available via a webcast and can be accessed at: http://www.wsw.com/webcast/rrshq13/accp.ob. The replay can be obtained at the same link for up to 90 days after the live presentation.

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SurgiQuest Announces First Single Port Procedure for Ovary Removal Using AirSeal(TM) Access System
2. Scientists call for more access to biotech crop data
3. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
4. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
5. Open Biosystems Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
6. Study Finds Broadband Access Key to Empowerment of Minority Communities
7. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
8. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
9. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio
11. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... The global Pyrogen Testing Market ... dominant share in the overall market. The leading players, ... Merck KGaA, held a lion,s share of 51% in ... that these companies are expected to retain their leadership ... do not require rabbit pyrogen testing along with strategic ...
(Date:11/30/2016)... , Nov. 30, 2016 Biotest Pharmaceuticals ... is pleased to announce the addition of its newest ... Kearney, Nebraska . The 15,200 square foot ... November 29th, 2016 and brings the total number of ... Ileana Carlisle , BPC,s Chief Executive Officer said ...
(Date:11/30/2016)... -  Equicare Health Inc ., the leading supplier of ... of the top 100 companies in the 2016 Global ... the top digital health companies across the globe.   ... year continually upgrading our product with the ongoing digital ... says Len Grenier , CEO of Equicare Health, ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/28/2016)... LONDON , Nov. 28, 2016 ... at a rate of 16.79%" The biometric system ... to grow further in the near future. The biometric ... 32.73 billion in 2022, at a CAGR of 16.79% ... biometrics system, integration of biometric technology in smartphones, rising ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
Breaking Biology News(10 mins):